Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Georg Tschank is active.

Publication


Featured researches published by Georg Tschank.


Immunopharmacology and Immunotoxicology | 1985

Effects of hydrazyl group containing drugs on leucocyte functions: an immunoregulatory model for the hydralazine-induced lupus-like syndrome.

Rudolf E. Schopf; Hartmut Hanauske-Abel; Georg Tschank; Hermann Schulte-Wissermann; Volkmar Gunzler

Isoniazid (INH) and hydralazine (HYD) are transglutaminase (TGase, E.C.2.3.2.13.) substrates containing catalytically recruitable hydrazyl groups. Since they can be expected to inhibit TGase-mediated cell functions by competing with physiological substrates, their effect upon allogeneically and lectin-induced proliferation of mononucleocytes and upon zymosan-induced chemiluminescence of phagocytes was studied. Both compounds inhibited chemiluminescence in a dose-dependent manner. ID50 of HYD was consistently below 20 microM, while that of INH was above 120 microM. Proliferation of immunocompetent cells was suppressed by HYD with an ID50 of 60 microM, INH was inhibitory only above 5000 microM. Analogs of both compounds not containing hydrazyl groups proved to be inactive. Control experiments indicated that inhibition is not due to toxicity or lipophilicity of the compounds, structural analogs lacking a hydrazyl moiety were inactive. It is suggested that, in vivo, HYD interferes with signal-induced TGase-dependent leucocyte functions essential for immunologic stability, and that the resultant dysregulation with disruption of self tolerance contributes to the HYD promoted lupus-like syndrome.


Biochemical Journal | 1994

Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues.

E Baader; Georg Tschank; K H Baringhaus; H Burghard; V Günzler


Hepatology | 1998

Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor

Martin Bickel; Karl-Heinz Baringhaus; Martin Gerl; Volkmar Gunzler; Jiri Kanta; Ludwig Schmidts; Michael Stapf; Georg Tschank; Klaus Weidmann; Ulrich Werner


Archive | 1994

Substituted heterocyclic carboxyamides, their preparation and their use as pharmaceuticals

Klaus Weidmann; Karl-Heinz Baringhaus; Georg Tschank; Martin Bickel


Archive | 1996

Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates

Klaus Weidmann; Karl-Heinz Baringhaus; Georg Tschank; Martin Bickel


Archive | 1994

Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments

Klaus Weidmann; Karl-Heinz Baringhaus; Georg Tschank; Martin Bickel


Archive | 1998

Substituted isoquinoline-3-carboxamides, their preparation and their use as pharmaceuticals

Klaus Weidmann; Karl-Heinz Baringhaus; Georg Tschank; Ulrich Werner


Archive | 2004

Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments

Karl Schoenafinger; Holger Wagner; Gerhard Jaehne; Holger Gaul; Christian Buning; Georg Tschank; Ulrich Werner


Archive | 2004

Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament

Holger Wagner; Karl Schoenafinger; Gerhard Jaehne; Holger Gaul; Christian Buning; Georg Tschank; Ulrich Werner


Archive | 1994

Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals

Klaus Weidmann; Karl-Heinz Baringhaus; Georg Tschank; Martin Bickel

Collaboration


Dive into the Georg Tschank's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge